United States Drug Patent 8,148,374: Claim Scope, Cobicistat Coverage, and Patent Landscape
US Patent No. 8,148,374 is directed to a selective cytochrome P450 3A inhibitor used as a pharmacokinetic enhancer for HIV and HCV medicines. The patent is associated with cobicistat, marketed by Gilead Sciences as Tybost and used in combination products including Stribild, Genvoya, and Symtuza. Its core commercial value is compound-level protection, supported by composition and cytochrome P450 inhibition claims.
The quoted claims omit the chemical structures after "A compound which is." In the issued patent, those structures are presented graphically or through chemical formulae. The exact boundaries of claims 1 and 5 therefore depend on the structural drawings, stereochemistry, salt definitions, and any incorporated specification language.
What drug does US Patent 8,148,374 protect?
US 8,148,374 protects cobicistat and closely defined chemical embodiments, including pharmaceutically acceptable salts. Cobicistat is a mechanism-based inhibitor of CYP3A used to increase systemic exposure to co-administered antiretroviral agents.
Commercial identity of the protected compound
| Item |
Information |
| Active ingredient |
Cobicistat |
| Development code |
GS-9350 |
| Initial sponsor |
Gilead Sciences |
| First FDA approval |
Tybost, 2014 |
| Therapeutic role |
Pharmacokinetic enhancer |
| Primary enzyme target |
CYP3A, particularly CYP3A4 |
| Main products |
Tybost, Stribild, Genvoya, Symtuza |
| Product type |
Small-molecule drug |
| Biosimilar pathway |
Not applicable |
| Generic pathway |
ANDA under Hatch-Waxman |
The patent does not protect an HIV protease inhibitor or HCV antiviral as the active therapeutic. It protects the enhancer used to raise concentrations of those drugs.
What are the claims of US Patent 8,148,374?
The claims fall into four principal categories: compound claims, composition claims, combination claims, and method-of-use claims.
Compound claims: claims 1 and 5
Claims 1 and 5 are directed to a compound and its pharmaceutically acceptable salts. These are the strongest claims in the set because they do not require a pharmaceutical formulation, a co-administered drug, or a particular patient-treatment step.
A compound claim generally captures:
- The claimed molecular structure.
- The specified stereochemical configuration.
- Pharmaceutically acceptable salts of that structure.
- Commercial manufacture and sale of the compound, subject to claim construction.
- Use of the compound in finished products, even where the product also contains other active ingredients.
Claim 5 appears to recite a separate structural embodiment or an alternative presentation of the same core invention. The omitted chemical drawing prevents a reliable distinction between claims 1 and 5 based only on the text supplied.
The commercial implication is direct: a generic manufacturer that makes cobicistat itself faces the principal infringement risk under the compound claims, independent of whether the generic product uses the same formulation or indication as Gilead's product.
Pharmaceutical composition claim: claim 2
Claim 2 covers a pharmaceutical composition containing the claimed compound or salt and a pharmaceutically acceptable carrier or excipient.
This claim reaches ordinary dosage forms, including:
- Tablets.
- Capsules.
- Oral solutions or suspensions.
- Solid dispersions.
- Granulated products.
- Other oral dosage forms containing cobicistat with conventional excipients.
Claim 2 is narrower than the compound claims because it requires a pharmaceutical composition. It remains commercially important where a generic applicant avoids a direct compound claim challenge but markets a finished dosage form containing the patented compound.
Combination composition claim: claims 3 and 4
Claim 3 requires the composition to contain at least one therapeutic agent metabolized by cytochrome P450. Claim 4 specifies broad categories of qualifying agents.
The listed categories include:
- HIV protease inhibitors.
- HIV non-nucleoside reverse transcriptase inhibitors.
- HIV nucleoside and nucleotide reverse transcriptase inhibitors.
- HIV integrase inhibitors.
- HIV entry, gp41, gp120, CXCR4, CCR5, and capsid inhibitors.
- HCV NS3 protease inhibitors.
- HCV NS5A inhibitors.
- HCV NS5B polymerase inhibitors.
- Ribavirin and interferons.
- Other HIV and HCV treatments.
- Hepatoprotective agents.
- Certain metabolic enzyme inhibitors.
The combination claim is drafted broadly enough to cover the pharmacokinetic-enhancer concept rather than a single co-formulated product. It may reach both fixed-dose combinations and separate administration of cobicistat with a qualifying therapeutic agent, depending on the claim language and infringement theory applied.
For current products, the most relevant combinations are those involving elvitegravir, darunavir, emtricitabine, tenofovir alafenamide, and other antiretrovirals. The claim language also extends to HCV combination concepts, even where no commercial HCV product ultimately became the main revenue driver.
How do claims 6 through 10 protect CYP3A inhibition?
Claims 6 through 10 are method claims directed to inhibiting cytochrome P450 monooxygenase in a patient.
Method claim hierarchy
| Claim |
Subject matter |
| 6 |
Administering the compound or salt to inhibit cytochrome P450 monooxygenase |
| 7 |
Inhibition of a CYP3A isoenzyme |
| 8 |
Inhibition of CYP3A4 |
| 9 |
CYP2C9 is not inhibited, or is inhibited substantially less than CYP3A4 |
| 10 |
The compound does not inhibit, or weakly inhibits, one or more protease enzymes |
Claims 8 through 10 narrow the method to the selectivity profile that distinguishes cobicistat from some earlier pharmacokinetic enhancers.
Why the CYP2C9 limitation matters
Claim 9 adds a selectivity requirement. A competing molecule that inhibits CYP3A4 but also materially inhibits CYP2C9 may fall outside the claim, depending on the construction of "substantially less." This limitation creates a technical design-around route for an alternative enhancer with a different cytochrome P450 profile.
The limitation also creates an evidentiary issue. In a litigation or ANDA dispute, the patent owner would likely rely on comparative enzyme inhibition data, cellular assays, metabolite data, and clinical pharmacokinetic evidence. The relevant comparison is not simply whether CYP2C9 is inhibited, but whether its inhibition is substantially lower than CYP3A4 inhibition.
Why claim 10 matters
Claim 10 addresses protease-enzyme inhibition. Ritonavir, the principal predecessor pharmacokinetic enhancer, has clinically relevant HIV protease inhibition. Cobicistat was designed to retain CYP3A inhibition while reducing antiviral protease activity.
This claim therefore supports the product-positioning distinction between cobicistat and ritonavir. It is narrower than claim 8 because it requires a particular absence or weakness of protease inhibition.
How strong is the patent estate for cobicistat?
US 8,148,374 has a strong core position if the accused product contains the claimed cobicistat structure. Compound claims generally provide the clearest infringement theory because they do not depend on:
- The indication selected by the generic applicant.
- The label language.
- The excipient system.
- The identity of the co-administered medicine.
- A specific CYP3A4 assay.
The principal weaknesses are technical and procedural:
- The exact chemical structure must be established from the issued patent.
- The claims may be vulnerable to anticipation or obviousness attacks based on earlier CYP3A inhibitors.
- Method claims can be affected by the generic label and induced-infringement evidence.
- Selectivity limitations in claims 9 and 10 may require difficult comparative testing.
- Salt, stereochemistry, polymorph, and solid-form distinctions can produce noninfringing alternatives if later patents cover those attributes separately.
The patent's strength is highest against a product containing cobicistat as the active ingredient. It is lower against a different CYP3A inhibitor designed around the patent's structural and selectivity limitations.
What formulations are protected by US 8,148,374?
The patent's composition claim covers cobicistat with a pharmaceutically acceptable carrier or excipient. It is not limited on its face to one tablet technology, excipient combination, or manufacturing process.
Potentially covered dosage forms include:
- Immediate-release oral tablets.
- Fixed-dose antiretroviral tablets.
- Cobicistat-containing combination tablets.
- Capsules and oral liquid formulations.
- Compositions containing conventional binders, fillers, lubricants, disintegrants, coatings, and stabilizers.
Later Gilead patents may provide narrower protection for:
- Specific polymorphs.
- Crystalline forms.
- Amorphous forms.
- Particle-size distributions.
- Solid dispersions.
- Chemical stability systems.
- Specific fixed-dose compositions.
- Manufacturing processes and intermediates.
Those later patents are commercially important because a generic applicant may avoid a formulation or solid-form claim while still confronting the broader compound claim in US 8,148,374.
What is the Orange Book status of US 8,148,374?
Cobicistat-containing FDA products are subject to Hatch-Waxman patent certification requirements. The relevant Orange Book analysis must be performed product by product because the listed patents can differ between Tybost, Stribild, Genvoya, and Symtuza.
The patent can affect an ANDA through:
- Paragraph III certification, accepting delayed approval until patent expiry.
- Paragraph IV certification, asserting that the patent is invalid, unenforceable, or not infringed.
- A 30-month stay if the patent owner or NDA holder files an infringement action within the statutory period.
- Potential pediatric exclusivity or patent-term-adjustment effects.
The statutory term is calculated from the applicable earliest effective nonprovisional or international filing date, not from the 2012 issue date. The final enforceable expiration date must be taken from the USPTO patent record and the applicable FDA Orange Book listing, including any patent-term adjustment or pediatric extension.
When does cobicistat lose exclusivity?
Cobicistat has two separate exclusivity layers:
- FDA regulatory exclusivity.
- Patent exclusivity.
The NCE exclusivity period for Tybost was limited to the FDA regulatory period and did not determine the full commercial protection period. Patent protection can extend beyond NCE exclusivity through the compound patent and later formulation, combination, and solid-form patents.
Exclusivity timeline
| Event |
Approximate timing |
| Cobicistat development |
Mid-2000s |
| US 8,148,374 issued |
April 3, 2012 |
| Tybost FDA approval |
2014 |
| NCE exclusivity |
Through approximately 2019 |
| Generic challenge opportunity |
After relevant Orange Book listing and certification |
| Compound patent endpoint |
Determined from effective filing date, PTA, and extensions |
| Later formulation and combination patents |
Potentially extend protection beyond the core patent |
A generic applicant can submit an ANDA with a Paragraph IV certification before patent expiry. Commercial launch remains constrained by litigation, settlement terms, pediatric exclusivity, other listed patents, and the scope of the generic label.
Which companies are challenging cobicistat patents?
The principal challenge risk comes from generic manufacturers developing ANDAs for cobicistat-containing products or antiretroviral combinations. Public litigation activity must be matched to the specific NDA and patent listing because an ANDA challenge to Tybost does not automatically resolve patent exposure for Genvoya or Symtuza.
Relevant potential challengers include large generic companies active in antiretroviral products, such as:
- Teva Pharmaceuticals.
- Mylan, now part of Viatris.
- Lupin.
- Dr. Reddy's Laboratories.
- Cipla.
- Aurobindo.
- Sandoz.
- Sun Pharma.
A definitive challenger list requires the relevant FDA paragraph IV notice, district-court docket, and NDA patent listing. A company may challenge one patent while accepting others or may use a section viii statement to omit a patented indication.
What patent litigation affects cobicistat?
Cobicistat litigation risk generally centers on three questions:
Compound infringement
Does the proposed product contain the exact claimed cobicistat structure or a covered salt? This is the most direct issue under claims 1 and 5.
Label-based induced infringement
Does the proposed generic label instruct use of cobicistat to inhibit CYP3A4 or to enhance exposure of a co-administered HIV or HCV medicine? Claims 6 through 10 may support an induced-infringement theory.
Invalidity
The likely invalidity grounds are:
- Anticipation by an earlier disclosed compound.
- Obviousness based on known CYP3A inhibitors.
- Lack of written description for the claimed selectivity profile.
- Lack of enablement across the full scope of the claims.
- Indefiniteness involving terms such as "substantially less" and "weakly inhibits."
The patent owner's best litigation posture is generally the compound claims. The generic applicant's strongest defenses may target prior-art compounds, claim construction, and the evidentiary basis for CYP2C9 and protease selectivity.
What licensing deals affect cobicistat?
Gilead retained the principal commercial position for cobicistat and used the compound in its own HIV combination portfolio. Commercial licensing and collaboration arrangements involving HIV fixed-dose combinations can affect commercialization without transferring ownership of the core patent.
Licensing analysis should distinguish:
- Patent ownership.
- Product commercialization rights.
- Regional distribution rights.
- Technology licenses for manufacturing.
- Licenses covering companion antiretrovirals.
- Settlements with ANDA applicants.
A collaboration involving elvitegravir, emtricitabine, or tenofovir does not necessarily license the cobicistat patent. Each agreement must be reviewed for field, territory, sublicensing, and patent-settlement terms.
How does cobicistat compare with ritonavir?
| Issue |
Cobicistat |
Ritonavir |
| Primary commercial role |
Pharmacokinetic enhancer |
Antiretroviral and enhancer |
| CYP3A inhibition |
Strong |
Strong |
| HIV protease inhibition |
Designed to be minimal |
Clinically significant |
| Main sponsor position |
Gilead |
AbbVie and earlier Abbott development |
| Small-molecule generic risk |
High after relevant patent expiry |
Mature generic market |
| Patent strategy |
Compound, combination, formulation, solid form |
Multiple compound, formulation, and combination patents |
| Main competitive threat |
Generic cobicistat and alternative boosters |
Generic ritonavir and alternative boosters |
Cobicistat competes with ritonavir on pharmacokinetic performance, tolerability, drug-interaction management, and combination-product design. The patent distinction is important: cobicistat's claims emphasize CYP3A inhibition with reduced protease inhibition.
What generic launch scenarios exist for cobicistat?
Scenario 1: Delayed launch after compound patent expiry
A generic applicant accepts the core patent and launches after the enforceable term ends. This produces the lowest litigation risk but delays market entry.
Scenario 2: Paragraph IV challenge
The applicant challenges validity or infringement. A timely suit can trigger the 30-month stay. Settlement may permit an authorized or licensed launch before the nominal patent endpoint.
Scenario 3: Label carve-out
A generic may omit a patented method of use under a section viii statement. This is less useful where the product's principal use is inseparable from the patented pharmacokinetic-enhancer method.
Scenario 4: Alternative booster
A manufacturer develops a different CYP3A inhibitor that does not meet the claimed structure or selectivity limitations. This avoids direct cobicistat infringement but faces separate development, regulatory, and clinical barriers.
What revenue exposure does the patent create?
Cobicistat is embedded in several high-value combination products. Revenue exposure is therefore greater than Tybost sales alone.
The principal protected commercial franchises include:
- Genvoya.
- Symtuza.
- Stribild.
- Tybost.
- Other cobicistat-containing regional products.
A generic cobicistat product could erode the enhancer market, but substantial revenue protection may remain if combination-product patents, regulatory exclusivities, clinical complexity, or separate patents covering active partners delay substitution.
The largest commercial risk arises when a generic can reproduce the same combination or obtain approval for a therapeutically interchangeable product. A standalone cobicistat ANDA does not necessarily create immediate substitution for every branded fixed-dose combination.
Key Takeaways
- US 8,148,374 is a core cobicistat patent associated with Gilead's pharmacokinetic-enhancer franchise.
- Claims 1 and 5 are compound claims and present the strongest direct infringement position.
- Claims 2 through 4 cover compositions and combinations with CYP450-metabolized HIV and HCV therapies.
- Claims 6 through 10 cover patient treatment using CYP inhibition, with narrower limitations for CYP3A4 selectivity and reduced protease inhibition.
- The quoted claim text omits the chemical structures, so the exact scope of claims 1 and 5 depends on the issued patent drawings.
- Cobicistat is a small molecule; biosimilar risk does not apply.
- Generic risk is governed by the Orange Book listing for the specific cobicistat-containing NDA, not by the patent number alone.
- Later solid-form, formulation, combination, and manufacturing patents may extend practical protection beyond the core compound patent.
- The compound claims are stronger against a cobicistat generic than the method claims are against a competitor using a different CYP3A inhibitor.
- The final patent expiration date requires review of the effective filing date, patent-term adjustment, pediatric exclusivity, and product-specific Orange Book records.
FAQs About US Patent 8,148,374 and Cobicistat
Is US 8,148,374 a patent for Tybost?
It is a core patent associated with cobicistat, the active ingredient in Tybost. Tybost may also be covered by additional formulation, combination, and product-specific patents.
Does US 8,148,374 cover Genvoya?
The patent can be relevant to Genvoya because Genvoya contains cobicistat. Genvoya's complete protection profile requires separate review of its Orange Book-listed patents and approved labeling.
Can a generic sell ritonavir without infringing US 8,148,374?
A ritonavir product does not infringe a cobicistat compound claim merely because ritonavir also inhibits CYP3A. The method claims require the claimed compound or salt.
Does the patent cover all CYP3A4 inhibitors?
No. The compound claims are structurally limited, and the method claims require administration of the claimed compound or salt. A different CYP3A4 inhibitor is not automatically covered.
What is the main design-around strategy?
The principal design-around route is to use a chemically distinct CYP3A inhibitor with a different CYP2C9 and protease-inhibition profile, while avoiding the claimed cobicistat structure, salts, compositions, and later formulation patents.
References
- U.S. Patent and Trademark Office. (2012). U.S. Patent No. 8,148,374: Pharmaceutical compositions and methods of use for inhibiting cytochrome P450 monooxygenase.
- U.S. Food and Drug Administration. (2014). Tybost (cobicistat) prescribing information.
- U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book.
- U.S. Food and Drug Administration. (2012). ANDA patent certification and exclusivity provisions under the Hatch-Waxman Amendments.
- U.S. Food and Drug Administration. (2016). Genvoya (elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide) prescribing information.
- U.S. Food and Drug Administration. (2018). Symtuza (darunavir, cobicistat, emtricitabine, and tenofovir alafenamide) prescribing information.
- Gilead Sciences, Inc. (2014). Cobicistat scientific and clinical development materials.
